{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:23:35Z","timestamp":1791887015688,"version":"4.3.4"},"reference-count":77,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"COBRE","award":["P30GM122733"],"award-info":[{"award-number":["P30GM122733"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Bacterial endophthalmitis (BE) is a potentially sight-threatening inflammatory reaction of the intraocular fluids or tissues caused by bacteria. Ciprofloxacin (CIP) eye drops are prescribed as first-line therapy in BE. However, frequent administration is necessary due to precorneal loss and poor ocular bioavailability. The objective of the current research was to prepare CIP containing nanostructured lipid carriers (CIP-NLCs) loaded an in situ gel system (CIP-NLC-IG) for topical ocular administration for enhanced and sustained antibacterial activity in BE treatment. CIP-NLCs were prepared by the hot homogenization method and optimized based on physicochemical characteristics and physical stability. The optimized CIP-NLC formulation was converted into CIP-NLC-IG with the addition of gellan gum as a gelling agent. Furthermore, optimized CIP-NLC and CIP-NLC-IG were evaluated for in vitro release and ex vivo transcorneal permeation studies, using commercial CIP ophthalmic solution (CIP-C) as the control. The optimized CIP-NLC formulation showed particle size, polydispersity index, zeta potential, assay and entrapment efficiency of 193.1 \u00b1 5.1 nm, 0.43 \u00b1 0.01, \u221232.5 \u00b1 1.5 mV, 99.5 \u00b1 5.5 and 96.3 \u00b1 2.5%, respectively. CIP-NLC-IG with 0.2% w\/v gellan gum showed optimal viscoelastic characteristics. The in vitro release studies demonstrated sustained release of CIP from CIP-NLC and CIP-NLC-IG formulations over a 24 h period. Transcorneal flux and permeability increased 4 and 3.5-fold, and 2.2 and 1.9-fold from CIP-NLC and CIP-NLC-IG formulations, respectively, when compared to CIP-C. The results demonstrate that CIP-NLC-IG could be considered as an alternate delivery system to prolong the residence time on the ocular surface after topical administration. Thus, the current CIP ophthalmic formulations may exhibit improved ocular bioavailability and prolonged antibacterial activity, which may improve therapeutic outcomes in the treatment of BE.<\/jats:p>","DOI":"10.3390\/pharmaceutics12060572","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T10:43:58Z","timestamp":1592563438000},"page":"572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Ciprofloxacin Loaded Nanostructured Lipid Carriers Incorporated into In-Situ Gels to Improve Management of Bacterial Endophthalmitis"],"prefix":"10.3390","volume":"12","author":[{"given":"Ahmed","family":"Youssef","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt"},{"name":"Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendar","family":"Dudhipala","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA"},{"name":"Research Institute of Pharmaceutical Sciences, University of Mississippi, Oxford, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/CMR.00113-16","article-title":"Bacterial and Fungal Endophthalmitis","volume":"30","author":"Durand","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/OPTH.S5778","article-title":"Impact of antibiotic resistance in the management of ocular infections: The role of current and future antibiotics","volume":"3","author":"Bertino","year":"2009","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.preteyeres.2006.12.001","article-title":"Bacterial endophthalmitis: Therapeutic challenges and host-pathogen interactions","volume":"26","author":"Callegan","year":"2007","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/bjophthalmol-2011-301439","article-title":"Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: Clinical features, causative organisms and post-treatment outcomes","volume":"96","author":"Simunovic","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcjo.2015.07.013","article-title":"Bacterial endophthalmitis: 10-year review of the culture and sensitivity patterns of bacterial isolates","volume":"50","author":"Assaad","year":"2015","journal-title":"Can. J. Ophthalmol."},{"key":"ref_6","unstructured":"(2020, February 14). The Incidence of Endophthalmitis after Cataract Surgery among the U.S. Medicare Population Increased between 1994 and 2001-Science Direct. Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0161642005004549."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00006982-200212000-00010","article-title":"Evaluating outpatient versus inpatient costs in endophthalmitis management","volume":"22","author":"Sulkes","year":"2002","journal-title":"Retina"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.survophthal.2018.02.003","article-title":"Management of bacterial postoperative endophthalmitis and the role of vitrectomy","volume":"63","author":"Clarke","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archopht.1995.01100120009001","article-title":"Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis","volume":"113","author":"Group","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ophtha.2006.08.038","article-title":"Endophthalmitis after Uncomplicated Cataract Surgery with the Use of Fourth-Generation Fluoroquinolones","volume":"114","author":"Moshirfar","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4103\/0301-4738.42418","article-title":"How to prevent endophthalmitis in cataract surgeries?","volume":"56","author":"Kelkar","year":"2008","journal-title":"Indian J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"ESCRS Endophthalmitis Study Group (2007). Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors. J. Cataract Refract. Surg., 33, 978\u2013988.","DOI":"10.1016\/j.jcrs.2007.02.032"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14787210.3.1.131","article-title":"Ocular bacterial infections: Current and future treatment options","volume":"3","author":"Kowalski","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/meajo.MEAJO_276_16","article-title":"Update on the Epidemiology and Antibiotic Resistance of Ocular Infections","volume":"24","author":"Miller","year":"2017","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/00003495-199651060-00010","article-title":"Ciprofloxacin","volume":"51","author":"Davis","year":"1996","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0161-6420(96)30416-8","article-title":"Comparison of Ciprofloxacin Ophthalmic Solution 0.3% to Fortified Tobramycin-Cefazolin in Treating Bacterial Corneal Ulcers","volume":"103","author":"Hyndiuk","year":"1996","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/02713683.2016.1188118","article-title":"Microbiological Isolates and Antibiotic Susceptibilities: A 10-Year Review of Culture-Proven Endophthalmitis Cases","volume":"42","author":"Liu","year":"2017","journal-title":"Curr. Eye Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/0149-2918(95)80058-1","article-title":"A review of the causes and treatment of bacterial and allergic conjunctivitis","volume":"17","author":"Friedlaender","year":"1995","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijpharm.2017.06.042","article-title":"Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol","volume":"529","author":"Balguri","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajo.2006.05.044","article-title":"Acute Endophthalmitis in Eyes Treated Prophylactically with Gatifloxacin and Moxifloxacin","volume":"142","author":"Deramo","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","first-page":"4428","article-title":"In Vitro Susceptibilities to Antimicrobials of Pathogens Isolated from the Vitreous Cavity of Patients with Endophthalmitis","volume":"43","author":"Benz","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: An overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"ref_23","first-page":"463","article-title":"Development and evaluation of prolonged release topical indomethacin formulations for ocular inflammation","volume":"55","author":"Adelli","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","article-title":"Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues","volume":"109","author":"Balguri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/jpet.119.256446","article-title":"Gellan Gum Based Sol-to-Gel Transforming System of Natamycin Transfersomes Improves Topical Ocular Delivery","volume":"370","author":"Janga","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1208\/s12248-014-9674-8","article-title":"Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion Technology: A Systematic Study Based on a Quality by Design Approach","volume":"17","author":"Patil","year":"2015","journal-title":"AAPS J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tatke, A., Dudhipala, N., Janga, K.Y., Soneta, B., Avula, B., and Majumdar, S. (2019). Melt-Cast Films Significantly Enhance Triamcinolone Acetonide Delivery to the Deeper Ocular Tissues. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11040158"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.xphs.2018.04.014","article-title":"Formulation Development, Optimization, and In Vitro\u2013In Vivo Characterization of Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications","volume":"107","author":"Patil","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tatke, A., Dudhipala, N., Janga, K.Y., Balguri, S.P., Avula, B., Jablonski, M.M., and Majumdar, S. (2019). In Situ Gel of Triamcinolone Acetonide-Loaded Solid Lipid Nanoparticles for Improved Topical Ocular Delivery: Tear Kinetics and Ocular Disposition Studies. Nanomaterials, 9.","DOI":"10.3390\/nano9010033"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40005-013-0087-y","article-title":"Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery","volume":"43","author":"Yoon","year":"2013","journal-title":"J. Pharm. Investig."},{"key":"ref_31","first-page":"4421","article-title":"A comprehensive review on solid lipid nanoparticles as delivery vehicle for enhanced pharmacokinetic and pharmacodynamic activity of poorly soluble drugs","volume":"12","author":"Dudhipala","year":"2019","journal-title":"Int. J. Pharm. Sci. Nanotechol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4155\/tde-2017-0088","article-title":"Recent advances in topical nano drug-delivery systems for the anterior ocular segment","volume":"9","author":"Lakhani","year":"2018","journal-title":"Ther. Deliv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2019.05.034","article-title":"Hydrogel-based ocular drug delivery systems: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations","volume":"306","author":"Cooper","year":"2019","journal-title":"J. Controlled Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jddst.2018.12.005","article-title":"Improving therapeutic efficacy of voriconazole against fungal keratitis: Thermo-sensitive in situ gels as ophthalmic drug carriers","volume":"49","author":"Okur","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1208\/s12249-009-9373-4","article-title":"Ciprofloxacin as Ocular Liposomal Hydrogel","volume":"11","author":"Hosny","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Patil, A., Lakhani, P., Taskar, P., Avula, B., and Majumdar, S. (2020). Carboxyvinyl Polymer and Guar-Borate Gelling System Containing Natamycin Loaded PEGylated Nanolipid Carriers Exhibit Improved Ocular Pharmacokinetic Parameters. J. Ocul. Pharmacol. Ther.","DOI":"10.1089\/jop.2019.0140"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/21691401.2018.1443117","article-title":"Ion sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: In vitro permeability, cytotoxicity and in vivo evaluation","volume":"46","author":"Janga","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0731-7085(03)00151-1","article-title":"Validation of an HPLC method for the determination of ciprofloxacin in human plasma","volume":"33","author":"Imre","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/10717544.2014.914986","article-title":"Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation","volume":"23","author":"Dudhipala","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dudhipala, N., and Gorre, T. (2020). Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson\u2019s Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12050448"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Poonia, N., Kharb, R., Lather, V., and Pandita, D. (2016). Nanostructured lipid carriers: Versatile oral delivery vehicle. Future Sci. OA, 2.","DOI":"10.4155\/fsoa-2016-0030"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1208\/s12249-019-1597-3","article-title":"Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects","volume":"21","author":"Dong","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tirumalesh, C., Suram, D., Dudhipala, N., and Banala, N. (2020). Enhanced pharmacokinetic activity of Zotepine via nanostructured lipid carrier system in Wistar rats for oral application. Pharm. Nanotechnol.","DOI":"10.2174\/2211738508666200225113359"},{"key":"ref_44","first-page":"4107","article-title":"Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin","volume":"9","author":"Han","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2147\/IJN.S190502","article-title":"Natamycin solid lipid nanoparticles\u2013sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: Preparation and optimization","volume":"14","author":"Khames","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.colsurfb.2010.07.047","article-title":"Preparation and physicochemical characterization of naproxen\u2013PLGA nanoparticles","volume":"81","author":"Javadzadeh","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2011.12.037","article-title":"Loading hydrophilic drug in solid lipid media as nanoparticles: Statistical modeling of entrapment efficiency and particle size","volume":"424","author":"Ghadiri","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_48","first-page":"167","article-title":"Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications","volume":"393","author":"Egea","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1211\/0022357011775190","article-title":"Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium","volume":"53","author":"Foster","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1023\/A:1012126301290","article-title":"The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent","volume":"14","author":"Desai","year":"1997","journal-title":"Pharm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s11095-012-0958-3","article-title":"Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery","volume":"30","author":"Kulkarni","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejpb.2016.10.022","article-title":"Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation","volume":"110","author":"Dudhipala","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/21691401.2017.1299160","article-title":"Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: Preparation, characterization and comparative pharmacokinetic evaluation","volume":"46","author":"Butreddy","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013Drug release and release mechanism","volume":"45","author":"Schwarz","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/21691401.2018.1465068","article-title":"Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: Preparation, characterization, permeation and pharmacokinetic evaluation","volume":"46","author":"Dudhipala","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_56","unstructured":"Sharma, A., Sood, A., Mehta, V., and Malairaman, U. (2016). Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin. Asian J. Pharm. Clin. Res., 356\u2013360."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Mamun, A.A., Kabir, M.T., Setu, J.R., Zaman, S., Begum, Y., and Amran, M.S. (2017). Quality Control Tests for Ophthalmic Pharmaceuticals: Pharmacopoeial Standards and Specifications. J. Adv. Med. Pharm. Sci., 1\u201317.","DOI":"10.9734\/JAMPS\/2017\/33924"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejps.2017.04.013","article-title":"Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide","volume":"104","author":"Morsi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1004494331895","article-title":"FTIR spectral characterization of thin film coatings of oleic acid on glasses: I. Coatings on glasses from ethyl alcohol","volume":"34","author":"Lee","year":"1999","journal-title":"J. Mater. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.apsusc.2009.11.079","article-title":"Re-examination of characteristic FTIR spectrum of secondary layer in bilayer oleic acid-coated Fe3O4 nanoparticles","volume":"256","author":"Yang","year":"2010","journal-title":"Appl. Surf. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Deore, R., Kavitha, K., and Tamizhmani, T. (2010). Preparation and Evaluation of Sustained Release Matrix Tablets of Tramadol Hydrochloride Using Glyceryl Palmitostearate. Trop. J. Pharm. Res., 9.","DOI":"10.4314\/tjpr.v9i3.56289"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/2231-4040.85541","article-title":"Qualitative analysis of controlled release ciprofloxacin\/carbopol 934 mucoadhesive suspension","volume":"2","author":"Sahoo","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s12272-011-1014-2","article-title":"Transmucosal.delivery of domperidone from bilayered buccal patches: In vitro, ex vivo and in vivo characterization","volume":"34","author":"Palem","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijbiomac.2015.12.077","article-title":"Application of Box\u2013Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity","volume":"85","author":"Baig","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40005-016-0232-5","article-title":"Quality by design approach.for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets.for improved oral delivery","volume":"46","author":"Narendar","year":"2016","journal-title":"J. Pharm. Investi."},{"key":"ref_66","first-page":"1","article-title":"Formulation and Optimization of Polymeric Nanoparticles for.Intranasal Delivery of Lorazepam Using Box-Behnken Design: In Vitro and In Vivo Evaluation","volume":"2014","author":"Sharma","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-8-6","article-title":"Lipid nanoparticles for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies","volume":"8","author":"Bhaskar","year":"2009","journal-title":"Lipids Health Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jddst.2015.10.017","article-title":"Combined.dosage form of pioglitazone and felodipine as mucoadhesive pellets via hot melt extrusion for.improved buccal delivery with application of quality by design approach","volume":"30","author":"Palem","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/03639045.2015.1104346","article-title":"Development, optimization and in vivo characterization of domperidone controlled release hot.melt extruded films for buccal delivery","volume":"42","author":"Palem","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3109\/03639045.2015.1024685","article-title":"Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded.solid lipid nanoparticles developed by central composite design","volume":"41","author":"Narendar","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/03639045.2017.1304957","article-title":"Lipid nanoparticles of zaleplon for improved oral delivery by.Box-Behnken design: Optimization, in vitro and in vivo evaluation","volume":"43","author":"Narendar","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drudis.2012.10.005","article-title":"Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers","volume":"18","author":"Gan","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/03639045.2012.665460","article-title":"Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir","volume":"39","author":"Seyfoddin","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2005.11.020","article-title":"W\/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention","volume":"111","author":"Alany","year":"2006","journal-title":"J. Control. Rel."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajps.2013.07.001","article-title":"The endocytosis and intracellular fate of nanomedicines: Implication for rational design","volume":"8","author":"Kou","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.foodhyd.2012.01.004","article-title":"Gelation of gellan\u2013A review","volume":"28","author":"Morris","year":"2012","journal-title":"Food Hydrocoll."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1039\/C7NJ00112F","article-title":"A novel hydrogel with dual temperature and pH responsiveness based on a nanostructured lipid carrier as an ophthalmic delivery system: Enhanced trans-corneal permeability and bioavailability of nepafenac","volume":"41","author":"Yu","year":"2017","journal-title":"New J. Chem."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/6\/572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:40:55Z","timestamp":1760175655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/6\/572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["pharmaceutics12060572"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12060572","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}